Patricia Gaule

TL;DR: Results suggest that assays based on the use of these antibodies could yield concordant results, and suggest that previously described differences in PD-L1 expression in tissue are independent of the antibody used and likely attributable to tumor heterogeneity, assay- or platform-specific variables, or other factors.

TL;DR: The preferential expression of discrete immune evasion pathways in lung cancer could participate in therapeutic resistance and support design of optimal clinical trials.

TL;DR: BreastMark is a powerful tool for examining putative gene/miRNA prognostic markers in breast cancer, and can act as a powerful reductionist approach to these more complex gene signatures, eliminating superfluous genes, potentially reducing the cost and complexity of these multi-index assays.

TL;DR: High levels of B7-H3 protein have a negative prognostic impact in lung carcinomas and is associated with smoking history, suggesting a nonredundant biological role of these targets.

TL;DR: Mice lacking immune inhibitory receptor VISTA or programmed death-1 homolog (PD-1H KO) on a BALB/c background spontaneously develop cutaneous and systemic autoimmune diseases resembling human lupus, and PD-1h activation could be effective for treatment of systemic and cutaneous l upus.